LianBio 2021 Equity Incentive Plan Non-Statutory Share Option AgreementNon-Statutory Share Option Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a share option granted by LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the LianBio 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations • Florida
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of September 14, 2021 by and between LianBio, LLC, a limited liability company organized under the laws of the State of Delaware, the United States of America (the “US”) (the “Company”), and Yizhe Wang, an American citizen whose passport number is [***] (the “Employee”).
LIANBIO 2021 EQUITY INCENTIVE PLAN Restricted Share Unit AgreementRestricted Share Unit Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a grant (the “Award”) of Restricted Share Units (“RSUs”) by LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the LianBio 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
PERFORMANCE-BASED NON-STATUTORY SHARE OPTION AGREEMENTPerformance-Based Non-Statutory Share Option Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a performance-based share option granted by LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the LianBio 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
This SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of December 14, 2021 (the “Amendment Effective Date”), is entered into by and between Lian Oncology Limited, a limited company incorporated under the laws of Hong Kong (“Lian Oncology HK”), LianBio Licensing, LLC, a Delaware limited liability company and an Affiliate of LianBio (“LianBio Licensing”), Lian Oncology, an exempted company organized under the laws of the Cayman Islands (“Lian Oncology”) (together, “Licensee”), and QED Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”). Licensee and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.”
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is made on December 15, 2021 (the “Effective Date”) by and among LianBio, an exempted company organized and existing under the laws of the Cayman Islands (“LianBio”) and LianBio Development (HK) Limited, a limited liability company organized under the laws of the Hong Kong Special Administrative Region (“LianBio Development”). Each of LianBio and LianBio Development is referred to herein as a “Party” and, collectively, as the “Parties”.
LIANBIO RESTRICTED SHARE UNIT AWARD AGREEMENTRestricted Share Unit Award Agreement • March 31st, 2022 • LianBio • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a grant (the “Award”) of performance-based Restricted Share Units granted by LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the LianBio 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
